LSTM - LifeStem International - Listet on OTCBB

[Perfomancer]

LSTM - LifeStem International - Listet on OTCBB

LSTM - LifeStem International merge with IAE - International Aerospace Enterprises, Inc.







LSTM being covered by Penny Stock Rockets this weekend, as a potential big mover for the coming week. <http://www.pennystockrockets.com> $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ $$$$$$$$$$$$$$$$$$$$$$$$$$$ Home About Rss 01/30 MOVERS:: LSTM-OTC Written by admin on January 31, 2009 ? 12:36 pm - Greetings, A very exciting line up for your consideration on Monday?s open. We have combed our systems for penny stocks on the move, or penny stocks which we feel are on the cusp of explosive gains. Here are three penny stocks in three different, very exciting, industries for your consideration this week. * Lifestem International (LSTM-OTC BB, 0.0199, <http://www.lifesteminternational.com)> This could be our most exciting pick of the week. Shares in stem cell companies have become explosive since the Obama administrations new direction in the promotion of these technologies. LifeStem has become very active, and is starting to break out. LSTM provides products and support toward the research of biotechnologies, as well as providing a service to collect, process and store adult stem cells. They are in the right business at the right time; keep a close eye on LSTM this week. Until next time, Penny Stock Rockets $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ $$$$$$$$$$$$$$$$$$$$$$$$$$$ This one looks to run hard next week..IMO All The Besst - Good Trading - Be Cool $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

.com/faq.htm
NEWS LINKS CalbaTech, Inc. Financials <http://finance.yahoo.com/q/is?s=clbe.ob> CalbaTech, Inc. Announces $999,926 Reduction in Debt; First Adult Stem Cell Harvesting Scheduled <http://biz.yahoo.com/prnews/080331/lam116.html?.v=78> CalbaTech, Inc. Files SEC form 10KSB, Annual Report <http://biz.yahoo.com/e/080331/clbe.ob10ksb.html> LifeStem, Inc. Announces Joint Venture Agreement with Major California Medical Institute <http://biz.yahoo.com/prnews/080220/law132.html?.v=26>

MANAGEMENT TEAM
James DeOlden, Esq. - Chief Executive Officer, Director
Mr. DeOlden, B.A. History (1996) from Virginia Commonwealth University J.D. (1998) from Whittier Law School, is an attorney admitted to the California Bar. Mr. DeOlden, in conjunction with being a founder of LifeStem International, Inc., maintains a minimum number of clients in his small law practice but is focused on the growth and development of LifeStem International, Inc. Mr. DeOlden currently represents or has represented both publicly traded and private companies, with the focus being on emerging growth companies in various stages of corporate existence or development.
Ed Deese - President, Chief Operating Officer, Director
Mr. Deese, B.S. Economics (1985) from the University of California, Irvine, has been involved in entrepreneurial business development for the past 17 years. Most recently, Mr. Deese has served in various interim capacities for publicly traded companies or subsidiaries thereof. Prior to this, Mr. Deese was a founder, Director, and Chief Operating Officer of Burstein Technologies, Inc., an Irvine, California bio-technology company. Prior to Burstein Technologies, Mr. Deese served in a variety of entrepreneurial ventures, including three companies that went public through IPOs.

SCIENTIFIC ADVISORY BOARD
Dr. Kary Mullis :: Nobel Laureate
Ph.D. Biochemistry, UC Berkeley
Dr. Mullis received the Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the 20th century, one that revolutionized genetic science and engineering. PCR has also been an enormous commercial success. The original patent was sold to Hoffman LaRoche for $300 million and has generated more than a billion dollars in revenue from royalties.
Dr. David O'Bryan
Ph.D. Medical Sciences/Biochemistry, BU Med School
Dr. O'Bryan is a former Senior VP at SmithKline Beecham Clinical Laboratories. He has more than 28 years experience in the clinical testing industry, including significant experience in developing new technologies. On behalf of SmithKline Beecham Clinical Laboratories he negotiated license agreements involving patented gene sequences used to diagnose diseases and secured the first license for nucleic acid testing. Dr. O'Bryan is also a recognized expert in laboratory instrumentation and automation in the commercial reference laboratory industry.
Dr. Gerald Huth
Ph.D. Physics/Electronics, Uppsala University, Sweden
In 1985, Dr. Huth founded Xsirius Scientific, Inc. Two subsidiaries, Xsirius Superconductivity, Inc. and Xsirius Photonics, Inc. had IPOs and traded on NASDAQ, with Xsirius Scientific having a market cap exceeding $100 million.
Dr. Jason Van Tassel, M.D.
M.D., Georgetown University School of Medicine, Washington D.C.
Dr. Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in the San Francisco Bay area. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California at Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery. Prior to practicing medicine in LA, Dr. Van Tassel worked at Hybritech Inc., where he performed research investigating manufacturing processes related to monoclonal antibody test assays. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Dept. of Neurosciences at San Diego State.

$$$$ and goes to NASDAQ - Listing $$$$ Strong Buy $$$$ $$$$

Market-Capital: 1,29 Mio. US$

Watch out boys.Boardmarks growing(90) 52 WEEK HIGH
05/1/08 - $11.40.We can see some paradise here.

Kurs-Ziel: 6,00 - 10+ US$, in einer Laufzeit von 4 - 8 Wochen.

Nach einer Technischen Analyse: unentdeckte Perle, Beste Aktie an der OTCBB.

LSTM Analysis Top of Form 1 Bottom of Form 1 Top of Form 2 Bottom of Form 2

Symbol Last Trade Date Change Open High Low Volume
LSTM 0.0199 Jan-30-2009 0.01 0.016 0.021 0.0135 5,881,200
Note: Canadian symbols now end in .c i.e SYMB.C
Analysis Overall Short Intermediate Long
Bullish (0.35) Neutral (0.24) Bullish (0.38) Bullish (0.44)

Outstanding shares: 64.3Mio shares
DeOlden (ceo/director) and Deese (coo/director) hold 75% majority or 49mil shares per 8k

Effective public float 15.3mil shares

Market-Capital: 1,29 Mio. US$



Today a Long White Candlestick was formed. This shows that the prices advanced significantly from open to close during the day under strong buying pressure.





LSTM.( PPS 0.0199. 56% up in two days )Signal strong buy. Very nice growing revenue.From company report .
Key Stats & Ratios Quarterly
Net Profit Margin 368.21%
Operating Margin 9.23%
Return on Average Assets 874.79%
Summary
LifeStem International, Inc., formerly CalbaTech, Inc., is focused on incubating life science based companies that are developing next generation products and technologies. The Company comprises four wholly owned subsidiaries, Molecula, Inc., KD Medical, Inc. (KD), LifeStem, Inc. and Molecularware, Inc. that serve markets in the life sciences research market. Molecula develops and sells numerous research reagents for cell transfection, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) purification, protein expression, gene expression analysis and other fundamental products.
23341 Del Lago
Laguna Hills, CA 92853
United States - Map
+1-949-4509910 (Phone)
+1-949-5971408 (Fax)

Monday open above 0.026...Hm...can be a great signal for huge run

WELCOME TO THE LIFESTEM BOARD..

WITH NEWS ABOUT THE OBAMA STEMCELL APPROVAL WE SOON SHOULD SEE THE SHARES OF LIFESTEM MOVE QUICKLY ... HOWEVER THE FLOAT IS NOW IN STRONG HANDS AND HOLDERS ARE NOT LIKELY SELLERS... WE HAVE RECENTLY HAD NEWS THAT THE COMPANY WILL POSSIBLE CHANGE DIRECTION ALONG WITH MANAGEMENT CHANGES... ALL THE BETTER.. AS LONG AS THE FLOAT DOESN'T CHANGE FROM THE APPROXIMATE 64 MILLION SHARES WE ARE ALL BOUND TO MAKE MONEY.... ...... REMEMBER LOOK AT THE CHART BELOW IF YOU AREN'T SURE THIS ISN'T THE BEST STOCK AROUND... IT'S THE STAIRWAY TO HEAVEN... LOW VOLUME ISN'T BAD FOR US AGAIN ------- HARD TO FIND SELLERS ,,, IMHO FORDGT
<http://stockcharts.com/h-sc/ui?s=LSTM&p=D&yr=0&mn=0&dy=28&id=p23437852999><htt p://stockcharts.com/h-sc/ui?s=LSTM&p=D&yr=0&mn=0&dy=28&id=p23437852999>


Market-Capital: 1,29 Mio. US$

Outstanding shares: 64.3Mio shares
DeOlden (ceo/director) and Deese (coo/director) hold 75% majority or 49mil shares per 8k

Effective public float 15.3mil shares

Market-Capital: 1,29 Mio. US$



Today a Long White Candlestick was formed. This shows that the prices advanced significantly from open to close during the day under strong buying pressure.



ITEM 2.01. Completion of Acquisition or Disposition of Assets.

LifeStem International, Inc. has entered into an agreement to acquire International Aerospace Enterprises, Inc., a Nevada company (IAE). IAE is involved in the acquisition and sales of military aircraft parts. By acquisition of IAE, LifeStem International is acquiring over Eleven Million Dollars ($11,000,000) in military aircraft parts that will form the basis of the new direction of the Company. There is a note to pay One Million Dollars ($1,000,000) for the newly acquired military aircraft parts. The note becomes due in June of 2010. LifeStem International has attempted for a number of years to launch its Stem Cell Microbank Service and the Company recognizes that such launch has been extremely difficult. Further, the Stem Cell Microbank Service relies upon adults having discretionary income and considering the current economy and the likely probability that the US economy is in a recession, management has determined that the necessary course of action for improving shareholder value is to enter into the business of military defense by selling needed airplane parts. Furthermore, due to budget deficits and the worldwide economic recession, management feels that the U.S. military, as well as the military of other nations, are more likely to buy spare and replacement parts for their existing aircraft than to build new aircraft. Subsequent to this initial acquisition, IAE is seeking to identify other potential acquisitions of surplus military parts in order to increase its asset base and create a larger portfolio of military aircraft parts for sale.

The next steps that the Company will take is to merge IAE into LifeStem International and rename the Company International Aerospace Enterprises, Inc. Following the name change, there will be a CUSIP change and a new trading symbol that will be issued by NASDAQ. The current subsidiaries in LifeStem International will be transferred out of LifeStem International to eliminate some outstanding liabilities as detailed in Exhibit 10.13, attached, and provide to IAE, upon completion of all expected transactions, a balance sheet that has greater assets and fewer liabilities and thereby allowing IAE to focus exclusively on the military aircraft parts business.

International Aircraft Enterprises has included an Executive Summary in order for investors to learn more about the newly acquired wholly-owned subsidiary.

LSTM merge with IAE and goes to NASDAQ - Listing $$$$ Strong Buy $$$$ Executive Summary International Aerospace Enterprises, Inc (“IAE”) is an innovative and aggressive provider of military aircraft spare parts that offers inexpensive aircraft spare parts that meet high quality manufacturing standards to the complex worldwide military/industrial establishment. This is a viable, highly profitable industry with excellent fundamentals to create value for current and future shareholders. IAE’s dedication to provide these military aircraft spare parts to the U.S. Defense Department and their International Allies is built on a platform of integrity and national respect for the end users of these parts. IAE owns approximately $11 Million in aircraft spare parts inventory available for marketing and sales. The company’s inventory will be maintained in a location with modern offices and warehouse manufacturing space that is climate controlled, sprinkler equipped, earthquake resistant and equipped with electronic surveillance and security systems. This inventory is readily available for sale to an established market and the Company believes this will result in significant revenue and profitability. The sales will be accomplished through IAE’s strategic Marketing, Sales and Distribution Consignment relationships with several national and internationally recognized companies. Strategy International Aerospace Enterprises has conducted primary and secondary research in the military aircraft spare parts industry on aftermarket sales opportunities. The research clearly points to unmet demands of military aircraft spare parts in the worldwide marketplace. IAE has identified a significant number of opportunities within this arena of the worldwide market. The size of the worldwide military industrial complex market and the demand for products and services to meet the needs of both the United States Military and its Allies exceeded $439.3 billion for the fiscal year 2006.
is a new stem cell trading site. <read_msg.aspx?message_id=35272439>



$$$$$$$$$$$$$$$$$$$$$$ LSTM - LifeStem International - Strong Buy $$$$$$$$$$$$$$$$$$$$$$$$$$$$